scholarly journals Facial Flushing with Food: The Auriculotemporal Syndrome

2012 ◽  
Vol 28 (3) ◽  
pp. 475-476 ◽  
Author(s):  
John Humphrey ◽  
Gregory Black ◽  
Laurianne Wild
1982 ◽  
Vol 48 (02) ◽  
pp. 156-161 ◽  
Author(s):  
E J P Brommer ◽  
M M Barrett-Bergshoeff ◽  
R A Allen ◽  
I Schicht ◽  
R M Bertina ◽  
...  

SummaryIntravenous infusion of desmopressin (DDAVP, 0.4 μg/kg b.w. in 12’) causes an increase in the level of extrinsic plasminogen activator, measured in plasma euglobulin fractions with added C1-inactivator on fibrin plates. A poor response or no response at all was elicited in two out of 21 patients with spontaneous thrombosis, 18/38 with hyperlipoproteinaemia and 10/14 with terminal renal insufficiency requiring haemodialysis.Haemodilution during the first 30’ after starting the DDAVP-infusion occurred both in responders and in non-responders; so did haemodynamic reactions: increase in heart rate, drop in diastolic blood pressure, facial flushing. The rise of fibrinolytic activity was shown not to be associated with decreased hepatic blood flow. Normal factor VIII-rises in “non-responders” indicate the responsiveness of the receptive organs, including the hypothalamus, to DDAVP.Despite a normal baseline level of fibrinolytic activity in the blood, as occurs for instance in terminal renal insufficiency, the vascular endothelium may be refractory to stimulation. In some patients, especially in type IV hyperlipoproteinaemia, a selective defect of the release of plasminogen activator is postulated. In subjects with low fibrinolytic activity at rest, as observed in spontaneous thromboembolism and in hypertriglyceridaemia, the failure to release plasminogen activator upon stimulation with DDAVP might be a consequence of an impairment of synthesis as well.


2009 ◽  
Vol 14 (6) ◽  
pp. 371-373 ◽  
Author(s):  
Joseph Lam ◽  
Julie Milligan
Keyword(s):  

2007 ◽  
Vol 83 (3) ◽  
pp. 1196-1197 ◽  
Author(s):  
Somshekar Ganti ◽  
Richard Milton ◽  
Leslie Davidson ◽  
Andrew Thorpe

2018 ◽  
pp. 277-282 ◽  
Author(s):  
Stefania Guida ◽  
Francesca Farnetani ◽  
Steven P. Nisticò ◽  
Caterina Giorgio Mariarosaria ◽  
Graziella Babino ◽  
...  

Background: Recent studies have highlighted new botulinum neurotoxin (BoNT) applications in the field of dermatology. Objective: To review current knowledge of BoNT use in dermatology. Methods: The literature of the last 5 years has been reviewed. Results: We describe interesting protocols of BoNT treatment for hyperhidrosis (HH), hypertrophic scars and keloids, Raynaud phenomenon, facial flushing, oily skin, psoriasis, Hailey-Hailey disease, and cutaneous lesions like painful lesions and periorbital syringomas. Conclusions: Several skin conditions eligible for BoNT treatment have been described. After the wide application for HH treatment, scars as well as vascular and inflammatory skin disorders, oily skin and cutaneous lesions represent fields of application of BoNT.


Sign in / Sign up

Export Citation Format

Share Document